Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

Published 31/08/2022, 19:52
Updated 31/08/2022, 20:40
© Reuters.  Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

© Reuters. Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

New molecular entity approvals drew a blank in August. NMEs are those active moieties that have not been previously approved by the FDA. This should be a cause of concern, as NME approvals are considered a measure of innovation in drug research.

The fortunate ones that could take their drugs past the finish line included bluebird bio, Inc. (NASDAQ: BLUE), Johnson & Johnson (NYSE: JNJ (NYSE:JNJ)), and Axsome Therapeutics, Inc. (NASDAQ: AXSM).

ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) faced rejection for expanding the label of its Nuplazid to be able to treat Alzheimer’s disease psychosis. CorMedix, Inc.’s (NASDAQ: CRMD) defencath application was shot down by the FDA for a second time. The review period for Amicus Therapeutics, Inc.’s (NASDAQ: FOLD) Pompe disease treatment was extended.

The Prescription Drug User Fee Act, or PDUFA, date is the period by which the FDA is required to rule on an application submitted by a sponsor company.

Here are the key PDUFA catalysts for the upcoming month:

Can Vertex’s Cystic Fibrosis Drug Snag a Label Expansion Company: Vertex (NASDAQ:VRTX) Pharmaceuticals Incorporated (NASDAQ: VRTX)

Type of Application: supplemental new drug application

Candidate: Orkambi

Indication: cystic fibrosis in children.

Date: Sept. 4

Orkambi, a combination of ivacaftor and lumacaftor, was first approved for cystic fibrosis in July 2015. The company is now seeking to expand the label of the drug to include children 12 months to less than 24 months old.

Cystic fibrosis is a rare genetic disease that leads to a build-up of thick mucus in the lungs and other organs. It is caused by a defect in or absence of the protein – “cystic fibrosis transmembrane conductance regulatory protein,” due to mutations in the CFTR gene.

Orkambi fetched Vertex sales of $772 million in 2021, down from $908 million a year ago. A potential label expansion could help reinvigorate sales.

Revance Frown Lines Treatment Awaits FDA Clearance Company: Revance Therapeutics, Inc. (NASDAQ: RVNC)

Type of Application: biologic license application

Candidate: daxibotulinumtoxinA

Indication: glabellar lines

Date: Sept. 8

DaxibotulinumtoxinA, or Daxi, is a next-gen neuromodulator product that is being evaluated to treat moderate to severe glabellar lines, aka frown lines, and is touted as a potential Botox rival. The original PDUFA date of Nov. 25, 2020, was not met due to COVID delays in inspecting manufacturing sites.

The FDA issued a complete response letter – a communication from the FDA regarding non-approvability of the treatment, in October 2021, citing issues with manufacturing sites. The company’s resubmitted BLA was accepted for review by the FDA in late April, with the new PDUFA date.

Can Second Time Be Charm For Spectrum Pharma Company: Spectrum Pharmaceuticals, Inc.’s (NASDAQ: SPPI)

Type of Application: BLA

Candidate: eflapegrastim

Indication: chemotherapy-induced neutropenia

Date: Sept. 9

Eflapegrastim, which is to be marketed under the trade name Rolontis, is a long-acting granulocyte-colony stimulating factor. It's a novel molecule for the treatment of neutropenia, with the potential to compete in a worldwide market that exceeds $6 billion, Spectrum said in an investor presentation.

Neutropenia is a condition where the neutrophil count is very low in the blood and it can be caused due to diseases that damage the bone marrow by certain medications, including chemotherapy.

Like Revance, the FDA’s decision on Spectrum Pharma’s Rolontis application was delayed from the original PDUFA date of September 2020. A year later, the drug regulator outrightly rejected the application, citing issues with the manufacturing sites in South Korea. The FDA accepted the resubmitted application and communicated the new PDUFA date.

Bristol-Myers Squibb Looks to Add To Its New Drug Launch Tally For 2022 Company: Bristol-Myers Squibb Company (NYSE: NYSE:BMY)

Type of Application: NDA

Candidate: deucravacitinib

Indication: plaque psoriasis

Date: Sept. 10

Bristol-Myers Squibb's deucravacitinib, if approved, would be the first tyrosine kinase 2 inhibitor approved for the treatment of any disease. Phase 3 data supporting the NDA submission demonstrated the drug’s superior efficacy relative to Amgen (NASDAQ:AMGN), Inc.’s (NASDAQ: AMGN) Otezla.

Otezla, which has been approved for multiple indications, generated sales of $2.3 billion for Amgen in 2021.

Bristol-Myers Squibb has been brisk with its first-in-class drug approvals this year, and if deucravacitinib is approved by the deadline, it would mark the third such drug approval of the year for the company, Fierce Biotech reported.

ObsEva Hopes For Uterine Fibroid Drug Nod In US After EU Approval Company: ObsEva SA (NASDAQ: OBSV)

Type of Application: NDA

Candidate: linzagolix

Indication: heavy menstrual bleeding

Date: Sept. 13

Linzagolix provides flexible dosing options for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

“A dosing option without hormonal ABT would be welcomed by the significant number of women who either have contraindications to or a personal preference to avoid the use of estrogen-based therapies, while also providing a dosing option for women in whom hormonal ABT is indicated,” the company’s chief medical officer Elizabeth Garner said in a statement.

The European Commission granted marketing authorization for linzagolix in June, and in the region it would be sold under the brand name Yselty,

bluebird Braces For Double Delight Company: bluebird bio

Type of Application: BLA

Candidate: eli-cel

Indication: cerebral adrenoleukodystrophy

Date: Sept. 16

Bluebird bio is coming off the successful clearance for Zynteglo, its cell-based gene therapy, for the treatment of beta-thalassemia in adult and pediatric patients requiring red blood cell transfusions. The approval secured in mid-August kickstarted a nice upward momentum in the stock.

If approved, eli-cel will be the first and only gene therapy for the treatment of early active CALD, a rare neurodegenerative disease that primarily affects young children and leads to irreversible loss of neurologic function and death.

See also: Is Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has Slowed

Will It Be Smooth Sailing For Heron’s Nausea Drug? Company: Heron Therapeutics, Inc. (NASDAQ: HRTX)

Type of Application: NDA

Candidate: HTX-019

Indication: post-operative nausea and vomiting

Date: Sept. 17

Heron sees a significant market opportunity for HTX-019, going by about 39 million surgical procedures done annually, where people are at risk for PONV. The regulatory application submitted in Nov. 2021 was accepted for review with a PDUFA goal date of Sept. 17.

Regeneron Seeks Another Label Expansion For Cancer Drug Company: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

Type of Application: Libtayo in combination with chemotherapy

Candidate: sBLA

Indication: Lung cancer

Date: Sept. 19

Libtayo, a PD-1 inhibitor jointly developed by Regeneron and Sanofi (EPA:SASY) (NASDAQ: SNY), has already been approved for three indications – two types of skin cancer and as a monotherapy option for lung cancer.

The companies are now attempting to get a fourth approval for the treatment, this time in combination with chemotherapy as a first-line treatment for advanced non-small cell lung cancer patients.

Will FDA Hear Out Fennec’s Argument For Its Hearing Loss Drug? Company: Fennec Pharmaceuticals Inc. (NASDAQ: FENC)

Type of Application: NDA

Candidate: Pedmark

Indication: ototoxicity

Date: Sept. 23

Pedmark is a unique formulation of sodium thiosulfate, and is being evaluated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to less than 18 years of age with localized, non-metastatic, solid tumors.

Fennec’s original application was handed with a CRL in November 2021 on the grounds of manufacturing issues. A resubmission was made and the FDA accepted it for review in April.

Will Amylyx’ Wait For Maiden FDA Nod End? Company: Amylyx Pharmaceuticals, Inc.’s (NASDAQ: AMLX)

Type of Application: NDA

Candidate: sodium phenylbutyrate/taurursodiol

Indication: amyotrophic lateral sclerosis

Date: Sept. 29

An FDA panel had earlier in March voted against approval of the drug, and the drug regulator later announced an extension to the review period. This pushed the PDUFA date from June 29 to Sept. 29. A new Adcom meeting was convened subsequently.

Given the drug is the only pipeline compound in Amylyx’ portfolio, it becomes all the more important for the company to push it past the finish line. On a positive note, the company snagged its first-ever nod in June, when Health Canada approved the combo treatment for ALS.

Sanofi-Regeneron On Cusp Of Getting Another Approval For Blockbuster Drug Company: Regeneron/Sanofi

Type of Application: sBLA

Candidate: Dupixent

Indication: prurigo nodularis

Date: Sept. 30

Dupixent is Sanofi-Regeneron combo’s blockbuster anti-inflammatory drug, which has been approved for multiple indications. The two companies are now knocking on the FDA’s door for getting approval for Dupixent in prurigo nodularis, a chronic inflammatory skin disease that causes extreme itch and skin lesions.

If greenlighted, Dupixent would be the first and only medicine approved specifically to treat prurigo nodularis in the U.S.

Adcom Calendar:

The Peripheral and Central Nervous System Drugs Advisory Committee has convened a meeting on Sept. 7, between 12 p.m. and 6:30 p.m., to discuss Amylyx’ NDA for sodium phenylbutyrate/taurursodiol powder for oral suspension, for the treatment of ALS.

The FDA’s Oncologic Drugs Advisory Committee Meeting will occur on Sept. 22-23, both days between 9 a.m. and 1:15 p.m., to discuss Spectrum Pharma’s NDA for poziotinib tablets for the treatment of patients with previously treated, locally advanced or metastatic non-small cell lung cancer harboring HER2 exon 20 insertion mutations.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.